Introduction
============

Multiple sclerosis (MS) is a clinical diagnosis based on the dissemination of lesions of the central nervous system (CNS) in time and space ([@b20]). Recent proposed diagnostic criteria for MS utilize MRI findings to document dissemination of CNS lesions in time and space ([@b12]; [@b19]). Optic neuritis (ON) may be the heralding manifestation of MS ([@b15]; [@b7]). More than 50% of adult patients who present with isolated ON will eventually develop other signs of MS ([@b16]). The risk stratification for the future development of MS in patients presenting with ON can be assessed by the number of white matter lesions on the baseline cerebral MRI study ([@b1]). The risk is increased in women and in those patients who have oligoclonal bands (OCB) in the cerebrospinal fluid (CSF) ([@b6]).

Incomplete transverse myelitis (ITM) can be the presenting feature of MS. Patients with ITM who develop MS are more likely to have asymmetric clinical findings, predominant sensory symptoms with relative sparing of motor systems, spinal cord lesions extending over less than two spinal segments, abnormal brain MRI, and OCB in the CSF ([@b14]; [@b28]). Measurement of spinal cord atrophy that reflects destructive, irreversible pathology in patients presenting with ITM has important implications for the early treatment of MS ([@b10]).

Central nervous system involvement in MS may be difficult to differentiate from other autoimmune diseases such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjogren syndrome (SS). Thus, a large number of patients with APS or SLE may be misdiagnosed as MS, but the exact proportion is unknown and may receive inappropriate treatment ([@b5]). A retrospective study in 82 patients with primary Sjogren syndrome reported that 40.2% had brain involvement, 15.8% optic neuropathy, and 35.4% spinal cord involvement ([@b4]). Thus, the differential diagnosis may require careful assessment of all clinical and MRI findings, serological results, and CSF analysis ([@b22]).

Our objective was to aid in the timely diagnosis of MS in patients who presented with CIS and thus employ the proper treatment early during the course of the disease.

Patients and methods
====================

We studied 25 consecutive patients (18 women, 7 men), age 30.6 (range: 17--49) presented in our clinic with CIS suggestive of MS. The inclusion and exclusion criteria of the CIS patients are listed in [Table 1](#tbl1){ref-type="table"}. The clinical, laboratory, and imaging findings were studied in all patients. Laboratory investigations included complete blood count, serum values of liver enzymes, bilirubin, albumin, glucose, creatinine, and urine analysis. In addition, erythrocyte sedimentation rate, C-reactive protein, antinuclear antibodies (ANA), double-stranded DNA (ds-DNA), complement C3/C4, and anti-cardiolipin (ACL) antibodies were also perfomed.

###### 

List of inclusion and exclusion criteria

  Inclusion criteria                                                                                          Exclusion criteria
  ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Optic neuritis                                                                                              Head trauma
  Diplopia                                                                                                    Neuropsychiatric disorder
  Internuclear opthalmoplegia                                                                                 Diabetes mellitus
  Myelitis                                                                                                    Hypertension
  Hemiparesis-paraparesis                                                                                     Cardiac failure
  Dysarthria                                                                                                  Hepatic failure
  Sensory symptoms                                                                                            Renal failure
  MRI criteria: 1 GD enhancing lesion1 infratentorial lesion1 juxtacortical lesion3 periventricular lesions   Thalassemia, Sickle cell disease, Iron defi ciency, B12 defi ciency

**Abbreviation:** MRI, magnetic resonance imaging.

All patients were evaluated for MS with CSF serology (cells, protein, glucose, IgG index), visual evoked potentials (VEPs), somatosensory evoked potentials (SEPs), and brain and cervical spinal cord MRI. Patients were imaged at baseline, at three month intervals, and one year. CSF oligoclonal bands were not included in the evaluation since it is not an available test in our hospital laboratory. For MS diagnosis, the revised McDonald criteria were employed ([@b19]). Dissemination in space was demonstrated by either MRI alone when three of the following conditions were met: a) at least one gadolinium-enhancing lesion or nine T2 hyperintense lesions if there was no gadolinium enhancing lesion; b) at least one infratentorial lesion; c) at least one juxtacortical lesion; and d) at least three periventricular lesions, or two or more MRI-detected lesions consistent with MS plus elevated CSF IgG index. Dissemination in time was demonstrated by either MRI (detection of gadolinium enhancing abnormality at least 3 months after the onset of the initial clinical event and if not at the site corresponding to the initial event detection of a new T2 lesion if it appeared at any time compared with the baseline scan performed at least 30 days after the onset of the initial clinical event), or by a second clinical attack.

None of the studied patients had history of head trauma, neuropsychiatric disorder, diabetes mellitus, hypertension, thalassemia, iron and B12 deficiency, cardiac, hepatic and renal failure ([Table 1](#tbl1){ref-type="table"}). Finally, the protocol was approved by the Institutional Review Board Committee.

Results
=======

The characteristics of all CIS patients are depicted in [Table 2](#tbl2){ref-type="table"}. There were 25 patients (18 women, 7 men), of 30.6 years mean age (range 17--49). The mean age of patients at onset of CIS varied from 26.9 years for ON to 29.2 years for the patient with seizures. The mean follow-up time was 18.9 months in patients with ON, 17.5 months in patients with ITM, 18 months in patients with brainstem syndrome. The mean disease severity on the expanded disability status scale (EDSS) performed at least one month after the CIS varied from 0.41 to 1. Only 12 woman had isolated ON, 7 had ITM, 3 had mild brainstem syndrome (2 with internuclear ophthalmoplegia (INO), 1 with dysarthria), and 1 had sudden onset of tonic-clonic seizures. The predominant neurological examination findings during the acute phase of the CIS were: reduced unilateral visual acuity in the patients with ON, paraparesis, Lhermitte sign, sensory symptoms, diplopia, dysarthria, and hemiparesis as shown in [Table 3](#tbl3){ref-type="table"}.

###### 

Characteristics of CIS patients

                                                                          ON                     ITM                   Brainstem syndrome
  ----------------------------------------------------------------------- ---------------------- --------------------- ---------------------
  Sex ratio (female/male)                                                 12/0                   3/4                   2/1
  Age at diagnosis mean +/−SD (range)                                     29.5 ± 16 (17--46)     28.9 ± 8.7 (20--42)   29.6 ± 12 (24--49)
  Age at onset of CIS mean +/−SD (range)                                  26.9 ± 10.3 (17--43)   28.7 ± 9.1 (19--37)   29.1 ± 9.6 (21--48)
  Follow up time mean months (range)                                      18.9 (9--60)           17.5 (3--26)          18 (17--29)
  Duration of disease mean months, (range)                                20.7 (9--61)           19.3 (4--26)          19.5 (17--29)
  Disease severity on EDSS[a](#tf2-1){ref-type="table-fn"} mean (range)   0.41 (0--1)            0.6 (0--2.5)          1 (1--1)

**Abbreviations:** CIS, clinically isolated syndrome; ON, optic neuritis; ITM, incomplete transverse myelitis; EDSS, expanded disability status scale.

**Note:** EDSS was assessed at least one month after the CIS.

###### 

Clinical data of CIS patients

  Neurological symptoms and signs   No. of patients (%)
  --------------------------------- ---------------------
  Optic neuritis                    12 (48%)
  Myelitis                          7 (28%)
  Internuclear opthalmoplegia       2 (8%)
  Seizures                          1 (4%)
  Paraparesis                       5 (25%)
  Lhermitte sign                    2 (8%)
  Sensory symptoms                  9 (36%)
  Diplopia                          3 (12%)
  Dysarthria                        1 (4%)
  Hemiparesis                       1 (4%)

**Abbreviations:** CIS, clinically isolated syndrome.

The paraclinical data of the patients are shown in [Table 4](#tbl4){ref-type="table"}. Twenty four patients had abnormal brain MRI consisted of periventricular MS-like white matter lesions and 9 (36%) patients had evidence of myelitis. Both brain and cervical cord MRI were positive in 7 cases (28%). VEP's were abnormal in 16 (64%) and SEP's in 6 (24%) patients. Nineteen patients (76%) had increased IgG index, while in 6 patients it was normal.

###### 

Paraclinical data of CIS patients: Initial 2/25

  Parameters                                        (+)           (−)
  ------------------------------------------------- ------------- -------------
  Initial brain MRI                                 23/25 (92%)   2/25 (8%)
  Brain MRI[a](#tf4-3){ref-type="table-fn"}         24/25 (96%)   1/25 (4%)
  Cervical SC MRI[a](#tf4-3){ref-type="table-fn"}   9 (36%)       16 (64%)
  VEP's                                             16/25 (64%)   9/25 (36%)
  SEP's                                             6/25 (24%)    19/25 (76%)
  CSF[b](#tf4-4){ref-type="table-fn"}/WBC           1/25 (4%)     24/25 (96%)
  CSF[b](#tf4-4){ref-type="table-fn"}/IgG INDEX     19/25 (76%)   6/24 (24%)

**Abbreviations:** CIS, clinically isolated syndrome; SC, spinal cord; VEP, visual evoked potentials; SEP, somatosensory evoked potentials; CSF, cerebrospinal fluid.

**Notes:**

Brain and cervical SC MRIs were considered (+) when findings were observed at any time during the 3 month intervals up to a year

bCSF serology was performed during the baseline evaluation.

Serological features of the patients are demonstrated in [Table 5](#tbl5){ref-type="table"}. ANA were positive in 5 (20%) and anti-ds-DNA in 2 (8%) of patients, but no patient had low complement (C3 or C4). ACL-ab was positive in only 3 (12%) patients.

###### 

Serological features of the patients

  Parameters    (+)       (−)         Not done
  ------------- --------- ----------- ----------
  ANA           5 (20%)   17 (68%)    3 (12%)
  Anti-ds-DNA   2 (8%)    17 (68%)    6 (24%)
  ACL-ab        3 (12%)   22 (88%)    0
  C3/C4         0         25 (100%)   0

**Abbreviations:** CIS, clinically isolated syndrome; ANA, antinuclear antibodies; ds-DNA, double-stranded DNA; ACL-ab, anticardiolipin antibodies; C3/C4, complement fractions C3 and C4.

Using the baseline and three-month MRI scans and the clinical and paraclinical data, 72% of patients with CIS developed definite MS according to the revised McDonald's criteria within one year, while 28% had no further neurological and MRI findings during this observation period.

Discussion
==========

Patients with CIS may develop MS ([@b13]). Clinically the identification of patients with a CIS at high risk to develop clinically definite MS remains difficult ([@b8]). Monthly brain MRI scans in patients with CIS showed that the majority of patients with an abnormal baseline scan were diagnosed with MS after three months ([@b18]). Application of the new McDonald criteria to patients with CIS suggestive of MS doubled the rate of diagnosis of MS within one year of presentation ([@b3]). It has been suggested that monthly triple-dose Gd-enhanced MRIs accurately detected inflammation which is an important factor in the pathogenesis of brain tissue loss in CIS patients ([@b17]).

Although a CIS could be indicative of MS, it might occasionally be the first manifestation of systemic autoimmune diseases such as SLE, APS, and SS. In these cases not only the clinical presentation but the MRI findings may be similar ([@b27]). Thus, serology tests, eg, ANA, C3, C4, and antiphospholipid antibodies, could help in the differential diagnosis of MS from the various connective tissue diseases. In the present study 20% of CIS patients had positive ANA and a few patients had other autoantibodies but there were no other findings to indicate evidence of SLE, primary SS, and APS according to the currently used criteria ([@b26]; [@b30]; [@b29]). Presence of various autoantibodies such as ANA in the serum of patients with MS is a frequent finding ([@b25]). Brain MRI can be inconclusive in patients with CIS but intrathecal synthesis of OCB are helpful in establishing the diagnosis of MS ([@b24]; [@b23]), thus the lack of OCB measurements is a limitation of our study. A new OCB test may also improve the conversion of a CIS to MS ([@b11]). Prediction of conversion from CIS to MS can be improved if CSF markers (either elevated tau or neurofilaments \[NfHSMI35\] are combined with MRI findings ([@b2]). On the contrary, serum antimyelin antibodies did not seem to permit earlier diagnosis of MS ([@b9]). Intrathecal B-cell clonal expansion in the CSF of patients with CIS, often precedes both OCB and multiple MRI lesions and is associated with a high rate of conversion to definite MS ([@b21]).

Conclusion
==========

Patients with MS deserve an accurate diagnosis, because new effective immunomodulatory treatments could modify the disease progression. It is obvious that definite diagnosis of MS must be obtained as early as possible in order to initiate early immunomodulatory treatment. We believe that frequent MRI scans during the first year after the CIS facilitate the early and accurate diagnosis of definite MS.
